Clinical Study

Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis

Table 2

B lymphoma patient characteristics.

Sera analysis
Responders
Nonresponders

Median age (years)56 (52–79)59
Gender (M/F)7/12/3
Histology
 Diffuse large B cells71
 Indolent14
Stage
 I/II32
 III/IV53
Treatment
 Rituximab monotherapy51
 Rituximab chemotherapy34